Healthcare Performance Marketing Executive to Drive Growth for Chief Outsiders Clients
Data-driven marketing executive Chris Bird to now drive EBITDA growth, new patient volume, and enhanced patient experiences for clients as a Chief Outsiders fractional CMO.
Chris Bird, CMO, Chief Outsiders
PHOENIX, ARIZONA, June 10, 2025 (GLOBE NEWSWIRE) -- Chris Bird, a data-driven marketing executive with 16 years of experience driving growth for private equity-backed healthcare groups, startups, and service-based companies, will now drive client revenue growth as a Fractional CMO for Chief Outsiders. Recently, Bird joined Chief Outsiders' team of more than 120 Fractional Chief Marketing Officers (CMOs) and Fractional Chief Sales Officers (CSOs).
'Recognized for building high-performing teams, Chris excels at aligning internal staff and external partners around clear strategies, accountability, and measurable results,' said Karen Hayward, West Region Managing Partner, Chief Outsiders. 'We're excited to add his deep healthcare industry experience to our battle-tested network of marketing professionals.'
According to the Chief Outsiders website, Bird specializes in performance marketing and builds scalable, ROI-focused programs. Having restructured multiple marketing operations to meet HIPAA standards, he also delivers a strong focus on compliance.
Healthcare Marketing Leadership
As a Chief Outsiders healthcare-focused Fractional CMO, Bird brings deep industry experience to drive growth at client companies. For example, he achieved a 33% YoY increase in new patients and 56% YoY increase in new patient revenue for a PE-backed dental group. He also grew revenue from $153 million to $650 million over a six-year period for a PE-backed eye care MSO.
Driving Growth Through Digital Marketing
In addition to his executive roles in healthcare, Chris brings a strong foundation in digital marketing built over two decades, including executive leadership positions at three national digital marketing agencies. Bird's expertise spans SEO, paid media, CRO, email marketing, social media, reputation management, and web development. He is known for building performance-driven digital programs that deliver measurable ROI, improve operational efficiency, and scale. Chris consistently aligns digital execution with bottom-line results.
To support his successful executive marketing career, Bird earned a Master of Business Administration in Global Management, graduating with honors from the Thunderbird School of Global Management in Arizona. He also received a Bachelor of Science in Business Administration from the Eller College of Management at the University of Arizona in Tucson, Arizona.
About Chief Outsiders
Mid-sized companies unlock market potential and accelerate growth with top-tier talent and technology from Chief Outsiders, the nation's leading provider of fractional sales and marketing services.
CEOs and business leaders drive sales and marketing strategy to make big things happen with instant access to the firm's cohesive, battle-tested team of more than 120 fractional executives, a diverse pool of world-class expertise. Each brings the experience of VP Sales, VP Marketing, or higher at one or more operating companies, including many Fortune 500 firms.
Team OutsidersTM leverages this same expertise to deliver on-demand enterprise-grade execution to power growth with efficiency and flexibility. GrowthGearsSM OS supports faster, smarter, and less risky growth. The industry's first AI-powered growth platform integrates both the comprehensive strategy of fractional executives and the precise execution of Team OutsidersTM. We built its transparent, client-friendly interface around Chief Outsiders' proven Growth GearsTM process.
Attachment
Chris Bird, CMO, Chief Outsiders
CONTACT: Maleia Wood Chief Outsiders mwood@chiefoutsiders.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Implantable Remote Patient Monitoring Devices Market to Grow 21.7% CAGR by 2029
"Innovation-Driven and Knowledge-Intensive: Implantable Remote Patient Monitoring Devices Seek Flexible, Integrated Solutions Amid Accelerating Market Timelines and Rising Competition" Boston, June 12, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the 'Global Implantable Remote Patient Monitoring Devices Market' is expected to grow from $7.6 billion in 2024 to $20.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 21.7% from 2024 to 2029. The report on the implantable remote patient monitoring (IRPM) device market analyzes market shares by product, indication and end users. It segments the market into device types, such as cardiovascular, brain, gastrointestinal, hematological, respiratory, and musculoskeletal monitoring devices. Indication consists of cardiovascular diseases, brain disorders, and diabetes End users include hospitals, clinics, and home healthcare settings. Additionally, it offers a study of the competitive landscape, regional analysis, consumer insights, and a supply chain analysis, helping stakeholders make informed decisions and identify strategic opportunities. This report is particularly relevant today because implantable remote patient monitoring (IRPM) devices are transforming healthcare by enhancing patient outcomes, lowering healthcare costs, and increasing accessibility. These devices facilitate continuous monitoring of chronic conditions, enabling real-time data collection and analysis, which can lead to early detection of complications and more timely interventions. The factors driving the market's growth include: Chronic Diseases and the Aging Population: The rise in chronic diseases and the global aging population increase the need for continuous health monitoring. Implantable devices help manage these conditions more effectively, reducing hospital visits and improving patient outcomes. Demand for mHealth Applications: mHealth apps are gaining in popularity for their convenience and real-time health data. They enhance implantable devices by providing comprehensive health data, driven by the widespread use of smartphones and rising awareness of the benefits of digital health. Improved Wireless Technologies: Advances in wireless tech, such as 5G, improve the reliability and efficiency of remote patient monitoring. These technologies enable faster data transmission and more stable connections, which are crucial for real-time health monitoring. Request a sample copy of the global market for implantable remote patient monitoring (IRPM) devices report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $6.5 billion Market size forecast $20.3 billion Growth rate CAGR of 21.7% from 2024 to 2029 Segments covered By product, disease indication, end user, and region Regions covered North America, Europe, Asia-Pacific, and the Rest of World (RoW) Market drivers Increasing prevalence of chronic diseases due to an aging population. Growing demand for mHealth applications. Improved wireless communication technologies. Interesting facts: Reducing Hospital Readmissions: Implantable RPM devices can decrease hospital readmissions by up to 30%, which is crucial for managing chronic conditions like heart failure. Innovative Power Sources and AI Integration: Some implantable devices are powered by the human body, eliminating the need for external batteries. Additionally, integrating artificial intelligence (AI) enhances their predictive capabilities, allowing real-time adjustments to patient care. The report addresses the following questions: What is the projected size and growth rate of the global market for implantable remote patient monitoring devices? The global market for implantable remote patient monitoring devices was valued at $6.5 billion in 2023 and is expected to reach $20.3 billion by the end of 2029, at a CAGR of 21.7% from 2024 to 2029. What are the key factors driving the growth of the market? These include the increasing prevalence of chronic diseases due to an aging population, growing demand for mHealth applications, and improved wireless communication technologies. What market segments does the report cover? The global market for implantable remote patient monitoring devices is segmented by product, indication, end user and region. Which indication segment will enjoy market dominance through the forecast period? The cardiovascular diseases segment will have that position. Which region has the largest share of the global market for implantable remote patient monitoring devices? North America holds the largest share of the market. Leading Companies Include: ABBOTT AVERTIX MEDICAL INC. BIOTRONIK BOSTON SCIENTIFIC CORP. CARDIAC RMS DEXCOM INC. EBR SYSTEMS INC. ENDOTRONIX INC. INJECTSENSE INC. IMPULSE DYNAMICS MEDICO S.R.L. MEDTRONIC PROFUSA INC. QURA LLC. VITALCONNECT Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, giving you the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we are offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. Purchase a copy of the report directly from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
4 hours ago
- Hamilton Spectator
First of Its Kind in the Region: KFSHRC Successfully Performs Endoscopic Sleeve Gastroplasty on Kidney Transplant Patient
RIYADH, Saudi Arabia, June 12, 2025 (GLOBE NEWSWIRE) — In a medical achievement considered the first of its kind in the region, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has successfully performed an endoscopic sleeve gastroplasty (ESG) on a patient who had previously undergone a kidney transplant, a case that requires meticulous management of immunosuppressive medications and the prevention of any complications that could jeopardize the transplanted organ. This procedure marks a significant advancement in providing safe treatment solutions for transplant recipients, to improve their graft survival and quality of life. Known as Endoscopic Sleeve Gastroplasty (ESG), the procedure differs from surgical sleeve gastrectomy in that it requires no abdominal incisions, which is important for transplant patients. Instead, it uses an endoscope inserted through the mouth to suture the stomach internally, effectively reducing its volume and enabling the patient to lose weight and improve overall health. The procedure aimed to address obesity and metabolic, which are among the leading factors that can negatively impact the health of a transplanted kidney, increase cardiovascular risk, and reduce long-term patient outcomes. The procedure was performed by a multidisciplinary team of medical experts, led by Dr. Ehab Abufarhaneh, Consultant in Adult Transplant Gastroenterology and Hepatology. The team included gastroenterologists, an upper GI surgeon, transplant surgeons, transplant Nephrology, and transplant anaesthesiologists, all supported by highly trained nursing staff to ensure the highest level of safety, with particular focus on managing the patient's immunosuppressive regimen—critical to preserving kidney graft function. This achievement underscores the pivotal role of KFSHRC's Organ Transplant Centre of Excellence as a leading medical environment capable of delivering precise interventions for complex transplant cases. By adopting innovative techniques tailored to the unique needs of transplant patients and developing treatment protocols that address post-transplant challenges, the centre reinforces its position as a regional referral hub for cases beyond the scope of conventional treatment pathways. The success of this procedure further exemplifies KFSHRC's ongoing commitment to delivering advanced, patient-centred healthcare and fulfilling its vision of being the optimal choice for patients supported by an integrated ecosystem of education, research, and clinical excellence that aligns with the ambitions of Saudi Arabia's health sector. It is noteworthy that KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit or contact our media team at mediacoverage@ . A photo accompanying this announcement is available at
Yahoo
4 hours ago
- Yahoo
Hospitals Are Drug Testing Mothers Without Consent, Fueling Family Separations
By junior year of high school, Desseray Wright was already a mother and didn't expect to become pregnant again so soon. The Bronx, New York, teen was juggling raising a toddler and dreaming about becoming a lawyer. Sometimes, she would hang out with her friends and occasionally smoked weed. Then one day, despite still getting her period, she found out she was pregnant. She was more than 24 weeks along — too late to consider an abortion. Because Wright smoked weed for several months into her pregnancy, she told a health care provider during a routine prenatal visit. It would be an admission she'd later regret. After giving birth at a Bronx hospital in 1995, she noticed a bag on her baby's scrotum, and demanded answers. Hospital staff told her her son had been drug tested, but didn't explain why. Then a social worker entered her room, questioning her about marijuana use. Within the first hour of her newborn son Trayquan's life, she had lost custody. 'I was honest and truthful with this lady,' recalled Wright, now 47 and a family defense practice policy advocate for the Bronx Defenders. She explained that back then she believed child protective services were only called when there were allegations of abuse. While some policies have changed since Wright's case nearly 30 years ago, health care advocates and legal experts Capital B interviewed said across the country these types of interventions and drug testing without consent still disproportionately target Black and brown mothers. At the center of the disparities, they say, are gaps in federal privacy laws — including the Health Insurance Portability and Accountability Act (HIPAA) — which do not require hospitals to inform patients when they are tested for drugs. Civil rights organizations, including those led by justice-impacted Black women like Wright, argue that these covert tests have fueled a long-standing pattern of criminalizing Black and brown women in family courts and separating families under the guise of child protection. These women turned their personal pain into advocacy, calling for legislation to close HIPAA loopholes to prevent other mothers from being swept into both the criminal and family court systems instead of parenthood. There has been legislation introduced in recent years in states like California, New York, and Tennessee — where women have been prosecuted for using drugs while pregnant — to inform expectant mothers that they and their newborn are being tested for drugs. They also have the choice to opt out of those tests. 'Disproportionate drug screening of Black mothers and newborns, without consent, adds to the excessive surveillance of Black families, and leads to an increase in foster care placements,' according to a May 2024 report released by New York State's Advisory Committee to the U.S. Commission on Civil Rights, 'Examining the New York Child Welfare System and Its Impact on Black Children and Families.' Last month, the New York state Senate Health Committee passed the Maternal Health, Dignity, and Consent Act on an 11-2 vote. This bill 'is a clear statement that pregnant people do not deserve to be surveilled or criminalized,' Jamila Perritt, who is an OB-GYN and president & CEO of Physicians for Reproductive Health, said in a statement after the bill's advancement on May 13. In Wright's case, child protective services required her to attend family court compliance hearings for parenting classes and a drug treatment program — even though, she said, in the 1990s those services weren't designed for adolescents or applicable to marijuana use. After months of juggling two children and long commutes on public transportation from the Bronx to mostly unhelpful referrals across most of the five boroughs, Wright made the difficult decision to drop out of high school to focus on getting her son back. Capital B has reached out to New York's Office of Child and Family Services via email for comment about its policies, but has not heard back as of publication. They did respond on June 10 to say that they do not comment on pending legislation. Advocates and survivors interviewed by Capital B often refer to the combined family, child welfare, and criminal legal systems as 'family-policing systems.' Pregnant people go into labor inside a hospital almost every day. Between contractions, they, or their partner, may be handed a flood of documents. Included may be a form with legal language that could authorize a nurse practitioner or physician to drug test both the birthing person and their newborn, without clear consent or probable cause. 'The hospitals that are participating in this, it's people of color who are more impacted, and at more disproportionate rates,' said Stephanie Jeffcoat, founder of Families Inspiring Reentry & Reunification 4 Everyone. The organization helps impacted parents navigate multiple interlocking systems such as the family and criminal justice systems, and is part of the steering committee working on establishing informed consent in California. Jeffcoat and Wright say the system is broken due to social workers and other professionals with mandated reporting credentials. Jasmine Sankofa, executive director of the nonprofit organization Movement for Family Power, which is dedicated to abolishing the family policing system, agrees with them. 'There really isn't any research that justifies the use of mandated reporting, the use of test and report,' Sankofa said, adding, 'It's bias based. It's not research based.' She added that 'studies have found that even if a pregnant person was using substances while they were pregnant — even if a child is born and is experiencing neonatal abstinence syndrome, for example — the recommended treatment is the approach is called, 'eat, sleep, and console.'' The best health care for a newborn isn't separation, nor is it to test and report their birthing parent to a family-policing system, Sankofa added. In cases where mom or baby test positive, child protective services are contacted. As the parent goes back and forth to court, the baby is first placed in a foster home, and because of the Adoption and Safe Families Act enacted by former President Bill Clinton in 1997, within 15 months 'states must initiate termination of parental rights proceedings, except in specified circumstances.' Despite her specific circumstances, the California child welfare system still took Jeffcoat's daughter, Harmony Faith Chase, from her nine years ago. Jeffcoat survived being raped, and found out she was pregnant too late for an abortion. At the time she was 28, unhoused, and struggled with substance use. She didn't have health insurance, couldn't afford an abortion, and had an estranged relationship with her mother, who had custody of her two older children. One day, she went to a hospital in Orange County for an eye infection. That's when she later learned she was tested for drugs. Jeffcoat's next visit to the hospital was when she delivered her daughter via C-section. The first hour of Harmony's life was interrupted when a social worker took her away from her mom's arms and was placed into the foster care system — never to be in the care of her mother again. 'I remember the feeling that I felt of losing my child,' said Jeffcoat, now 37. In 2023, a bill was introduced in California that would, in part, prohibit medical personnel from performing a drug or alcohol test or screen on a pregnant person or a newborn without prior written and verbal informed consent, and would require the test or screen to be medically necessary to provide care. That bill failed to advance from the state's Senate health committee in March 2023. Jeffcoat is currently studying law to become an attorney in dependency law. 'I feel like my own attorney failed me,' she said. 'I want to really be up in there [court] making sure that parents aren't losing their kids to the system. Especially in the timeframe of the adoption, it should not have been able to take place in six months. It takes longer for people to be sentenced to jail or prison.' Jeffcoat said she lost custody of Harmony in 2017 while incarcerated for 6½ months for a probation violation. Family court proceedings went on without her being present. Once released, she spiraled deeper into her addiction. In 2019, she had a fight with another unhoused person about her bike. After waking up nearby a dumpster, it was the moment she said she decided to turn her life around. She contested the adoption. In 2021, she found the adopting parents. For three years, Jeffcoat said she reached out to them with hopes to create a post-adoption agreement to at least regain visitation rights, to no avail. 'I needed to make sure that I get into a position to ensure that they do not continue to do this to other people,' said Jeffcoat, who launched her nonprofit in 2023. Perritt, the doctor who is also a fellow of the American College of Obstetricians and Gynecologists and the Society of Family Planning, said people 'universally enter' health care professions 'because they want to change social justice issues, but during the course of medical education and training you are taught to conform to a system that exists already in order to survive it.' The history of the medical field being white and male, increases Perritt's beliefs that health care professionals teaming up with police goes back to the country's Founding Fathers. 'The police, to me, are not simply somebody in a police uniform. It's also the doctors, it's also the nurses, it's also the social workers. It's any and everybody who's a mandatory reporter.' Hospitals and health care providers often set their own drug testing and reporting policies — ones that can conflict with the ethical standards taught in medical training, particularly around informed consent and patient trust. In a notable shift, Mass General Brigham, a major hospital system in Boston, stopped automatically filing child neglect reports solely based on a newborn testing positive for drugs, citing a need to reduce unnecessary family separations. Drug testing shouldn't be considered a family testing system, advocates said. In 1996, after Wright lost custody of Trayquan, who was placed in her father's care, her troubles with the family-policing systems continued when she got pregnant with her third child and second son, Hassan. With an ongoing family court case, the newborn was immediately taken away and placed into a foster home in Brooklyn, New York. Hassan was there for nearly four years. Child protective services continued to return to Wright's life twice: when she went to federal prison for 10 years for a weapons and drug conviction, and survived a domestic violence incident by calling 911. After Wright was released from federal prison in 2013, she earned a criminal justice degree from John Jay College of Criminal Justice. She mourned the loss of her oldest daughter to gun violence in 2018, and in 2021 held on tight to Hassan, now 28, when he survived being shot. 'I graduated at the top of my class,' Wright said. The post Hospitals Are Drug Testing Mothers Without Consent, Fueling Family Separations appeared first on Capital B News.
